VelosBio CEO: Series A Success Shows Investors Back His ADC Formula

 
• By Sten Stovall
  
Generate a summary of this article
Listen to this article
Beta

VelosBio's well-backed Series A funding round showed that investors believe his team has identified the right combination of cancer target, linker and payload for creating a successful novel ADC, the biotech's CEO told Scrip.

R&D
Investors Have Told VelosBio Not To Reveal Its ADC R&D Target Yet • Source: Shutterstock

Developing and getting approved an antibody drug conjugate against cancer boils down to getting the right ADC formula comprising a targeted tumor, linker and payload, and VelosBio's CEO David Johnson says he and his team believe they have identified those components and that investors showed similar belief by backing the Seattle-based biotech's recent $58m Series A funding round.

VelosBio Inc. describes itself as a next generation oncology company which is developing antibody drug conjugates to target solid...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.